Brendan Lindgren, DO
Neurology · Colorado Springs, CONPI 1508329459
Payments from drug & device makers
What this record shows
This record is dominated by grants: $90,000 of the $104,954 with a category attached, or 85.8%. Biogen accounts for 86.9% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2023 at $90,046 and has fallen 85.4% since, to $13,179 in 2025. Among neurology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 239 payments — averaging $439.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$91K
- Genentech USA, Inc.$9K
- TG Therapeutics, Inc.$1K
- Pfizer$782
- AbbVie$703
- EMD Serono, Inc.$639
- plus $2K from 24 others
What the payments were for
- Consulting fees$7,9488%
- Grants$90,00086%
- Travel & lodging$1,0011%
- Food & beverage$5,9046%
- Education$1010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 23 | $91,205 |
| Genentech USA, Inc. | 10 | $8,583 |
| TG Therapeutics, Inc. | 30 | $1,205 |
| Pfizer | 51 | $782 |
| AbbVie | 33 | $703 |
| EMD Serono, Inc. | 19 | $639 |
| AstraZeneca | 14 | $402 |
| Novartis | 14 | $218 |
| Merz Pharmaceuticals, LLC | 5 | $147 |
| Vanda Pharmaceuticals Inc. | 4 | $135 |
| Amgen | 4 | $115 |
| Sanofi | 4 | $110 |
| SK Life Science, Inc. | 3 | $93 |
| Neurocrine Biosciences, Inc. | 3 | $78 |
| Lundbeck LLC | 3 | $60 |
| Argenx US, Inc. | 2 | $54 |
| Harmony Biosciences LLC | 2 | $50 |
| ANI Pharmaceuticals, Inc. | 2 | $39 |
| Acadia Pharmaceuticals Inc | 2 | $37 |
| Neurelis, Inc. | 1 | $35 |
| UCB, Inc. | 1 | $34 |
| Tanabe Pharma America, Inc. | 1 | $33 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $33 |
| Catalyst Pharmaceuticals, Inc. | 1 | $31 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Eisai Inc. | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Averitas Pharma Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$104,954 in reported general payments places this provider in the 90th percentile of 334 neurology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 16 | $285 |
| Gabapentin | 16 | $262 |
Paid to pharmacies, not to this prescriber.
Other neurology in Colorado Springs
- Kimberly WagnerColorado Springs$107K
- Bradley PriebeColorado Springs$100K
- Aparna KomatineniColorado Springs$71K
- Michelle RaphaelColorado Springs$19K
- Tamara MillerFort Collins$1.4M
- Justin MoonDenver$1.4M
- Ravi ShahParker$1.3M
- Rajeev KumarEnglewood$955K
- Marc TreihaftEnglewood$673K
- Jeffrey BennettAurora$605K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.